Azithromycin Alone is Sufficient
For a 6-year-old child with a three-week dry cough and lymphocytosis, azithromycin alone is the appropriate treatment—there is no indication to add augmentin (amoxicillin-clavulanate). The clinical presentation strongly suggests pertussis (whooping cough) or an atypical bacterial infection (Mycoplasma pneumoniae or Chlamydophila pneumoniae), and azithromycin provides optimal coverage for these pathogens.
Clinical Reasoning
Why This is Likely Pertussis or Atypical Infection
The combination of:
- Three-week duration of cough (prolonged, consistent with pertussis)
- Dry cough (typical of pertussis and atypical pathogens)
- Lymphocytosis (characteristic laboratory finding in pertussis)
These features point away from typical bacterial pneumonia caused by Streptococcus pneumoniae or Haemophilus influenzae, which would be the primary targets for augmentin.
Azithromycin is the Guideline-Recommended Treatment
For pertussis in children aged >6 months, azithromycin is the preferred first-line agent 1. The CDC guidelines specify:
- Dose: 10 mg/kg (maximum 500 mg) on day 1, followed by 5 mg/kg per day (maximum 250 mg) on days 2-5
- Total duration: 5 days
For atypical pneumonia (Mycoplasma or Chlamydophila), azithromycin is also the preferred agent 2:
- Same dosing regimen as above
- Azithromycin has superior efficacy against these organisms compared to beta-lactams
Why Not Add Augmentin?
Augmentin provides no additional benefit in this scenario:
No typical bacterial pneumonia indicators: The child lacks features suggesting S. pneumoniae or H. influenzae infection (which would present with productive cough, fever, focal lung findings, and neutrophilia rather than lymphocytosis)
Azithromycin covers the likely pathogens: Bordetella pertussis, Mycoplasma pneumoniae, and Chlamydophila pneumoniae are all macrolide-sensitive organisms 1, 2
Increased adverse events without benefit: Adding augmentin would significantly increase the risk of:
No guideline support for combination therapy: Neither the CDC pertussis guidelines 1 nor the pediatric pneumonia guidelines 2 recommend combining a macrolide with a beta-lactam for outpatient treatment of atypical infections
When Combination Therapy IS Indicated
Combination therapy (beta-lactam + macrolide) is reserved for hospitalized children with community-acquired pneumonia when:
- The child requires inpatient care
- Both typical (S. pneumoniae) and atypical (Mycoplasma/Chlamydophila) pathogens are significant considerations
- The clinical presentation suggests bacterial pneumonia with possible atypical co-infection 2
This does not apply to your outpatient scenario.
Common Pitfalls to Avoid
Over-prescribing broad-spectrum antibiotics: Using augmentin when azithromycin alone is sufficient contributes to antimicrobial resistance and increases adverse events 5, 6
Misinterpreting prolonged cough: A three-week dry cough with lymphocytosis is classic for pertussis or atypical infection, not typical bacterial pneumonia requiring beta-lactam coverage
Ignoring the lymphocytosis: This laboratory finding is a key diagnostic clue pointing toward pertussis, which requires macrolide therapy only
Practical Management
Prescribe azithromycin monotherapy:
- 10 mg/kg (max 500 mg) on day 1
- 5 mg/kg (max 250 mg) on days 2-5
Monitor for:
- Cough improvement within 5-7 days
- Resolution of symptoms by 2-3 weeks
- Gastrointestinal side effects (occur in ~6% of children) 3
Consider pertussis testing if available, as this has public health implications for contact tracing and prophylaxis 1
Do not add augmentin unless the clinical picture changes to suggest typical bacterial pneumonia (fever, productive cough, focal findings, neutrophilia).